All research papers

Results from the AAPM Task Group 324 respiratory motion management in radiation oncology survey.

Good practices for ⁶⁸Ga radiopharmaceutical production.

[¹⁷⁷Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.

Commissioning an Exradin W2 plastic scintillation detector for clinical use in small radiation fields.

Accuracy and consistency of intensity-based deformable image registration in 4DCT for tumor motion estimation in liver radiotherapy planning.

Head-to-Head Comparison of [⁶⁸ Ga]Ga-FAPI-46-PET/CT and [¹⁸F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer.

Evaluation of the Hybrid Tracer Indocyanine Green- 99m Tc-Nanocolloid for Sentinel Node Biopsy in Bladder Cancer-A Prospective Pilot Study.

Very-Low-Dose Radiation and Clinical Molecular Nuclear Medicine.

Analysis of Pros and Cons in Using [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer.

Efficiency of ¹²⁴I radioisotope production from natural and enriched tellurium dioxide using ¹²⁴Te(p,xn)¹²⁴I reaction.

What are useful methods to reduce occupational radiation exposure among radiological medical workers, especially for interventional radiology personnel?

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.

Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin.

Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.

Discharges of Nuclear Medicine Radioisotopes: The Impact of an Abatement System.

Integrated MRI-guided radiotherapy - opportunities and challenges.

Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.

A case report of radiopharmaceutical needlestick injury with scintigraphic imaging and dose quantification.

The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer.

Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by ⁶⁸Ga-FAPI-PET imaging.

AAPM task group report 302: Surface-guided radiotherapy.

Modified electron beam output calibration based on IAEA Technical Report Series 398.

A dosimetric comparative analysis of Brainlab elements and Eclipse RapidArc for spine SBRT treatment planning.

Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review.

Radiolabeled Gold Nanoseeds Decorated with Substance P Peptides: Synthesis, Characterization and In Vitro Evaluation in Glioblastoma Cellular Models.

Evaluation of the annual occupational effective doses in a SPECT/CT department.

Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.

Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in the Evaluation of Advanced Lung Cancer.

Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [⁶⁸Ga]Ga-OncoFAP-DOTAGA.

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.

Dosimetric evaluation of irradiation geometry and potential air gaps in an acrylic miniphantom used for external audit of absolute dose calibration for a hybrid 1.5 T MR-linac system.

Radiation Safety and Accidental Radiation Exposures in Nuclear Medicine.

Varian ethos online adaptive radiotherapy for prostate cancer: Early results of contouring accuracy, treatment plan quality, and treatment time.

¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

Occupational radiation dose of personnel involved in sentinel node biopsy procedure.

Correlation of ⁶⁸Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study.

Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus (SPARTACUS): A Multicenter Prospective Trial Evaluating Acute Toxicities and Patient Reported Outcomes.

Stereotactic Proton Ablative Radiosurgery of the Spine.

A Dosimetric Study Comparing Two Beam Arrangement Strategies in Fractionated Thoracic Spine Stereotactic Body Radiotherapy (SBRT) Planning.

Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.

Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study.

Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer.

On site production of [¹⁸F]PSMA-1007 using different [¹⁸F]fluoride activities: practical, technical and economical impact.

Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening.

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?

Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.

Nuclear medicine staff exposure to ionising radiation in ¹⁸F-FDG PET/CT practice: a preliminary retrospective study.

Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of ⁶⁸Ga-Labeled FAPI Dimer.

Fibroblast activation protein targeted therapy using [¹⁷⁷Lu]FAPI-46 compared with [²²⁵Ac]FAPI-46 in a pancreatic cancer model.

Deep learning based synthetic-CT generation in radiotherapy and PET: A review.

Nontoxic electron collimators.

Evaluation of inter- and intra-fraction 6D motion for stereotactic body radiation therapy of spinal metastases: influence of treatment time.

The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.

Sensitivity and specificity analysis of 2D small field measurement array: Patient-specific quality assurance of small target treatments and spatially fractionated radiotherapy.

A new 2D-3D registration gold-standard dataset for the hip joint based on uncertainty modeling.

Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients.

Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning.